Assembly Biosciences, Inc.

As of June 30, 2026, Assembly Biosciences, Inc. carries a market capitalization of 480.38M, placing it among publicly traded companies globally. Its enterprise value stands at 202.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Assembly Biosciences, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Assembly Biosciences, Inc. has 19.85M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 5.94, and the price-to-book ratio stands at 1.80.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 202.02M versus a market cap of 480.38M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Assembly Biosciences, Inc. maintains a current ratio of 13.99, meaning it holds 14.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Assembly Biosciences, Inc. posted a negative return on equity (ROE) of -0.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.02, reflecting losses generated across the asset base. The company generates approximately 897,422.31 in revenue per employee across its workforce of 73.00, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Assembly Biosciences, Inc.'s stock has declined approximately 24.29% over the past 52 weeks. The 50-day moving average sits at 23.94, while the 200-day moving average is 23.73.

Over the twelve months ended June 30, 2026, Assembly Biosciences, Inc. generated 65.51M in revenue and converted that into -36,762.60 in net income, yielding earnings per share of 0.00. EBITDA reached -7.60M, while operating income came in at -7.70M.

As of June 30, 2026, Assembly Biosciences, Inc. holds 280.41M in cash and equivalents against 2.06M in total debt, resulting in a net debt position of -28.26M. Total book value stands at 267.53M, with working capital of 266.56M providing operational flexibility.

Assembly Biosciences, Inc. produced -33.68M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -74,400.50 in capital expenditures, free cash flow totaled -33.76M - equivalent to -2.10 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -11.75 and net profit margin of -0.06 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.68: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -51.25, meaning Assembly Biosciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Assembly Biosciences, Inc.'s most recent stock split took place on February 12, 2024 with a 12:1 split ratio.

As of June 30, 2026, Assembly Biosciences, Inc. has an Altman Z-Score of 10.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.